

Collaborative Working Project Executive Summary

Improving Lung Cancer early detection rates, ensure equitable access to lung health checks and reduce health inequalities.

Project Title

A collaborative Working Agreement between NHS South West London ICB and Johnson and Johnson, to address disparities in lung cancer diagnosis and treatment outcomes by leveraging artificial intelligence (AI) tools and local data insights.

Partner Organisations

NHS South West London ICB, 120 The Broadway, Greater, London SW19 1RH

Johnson and Johnson, 50-100 Holmers Farm Way, High Wycombe HP12 4EG.

Project Rational

Lung cancer is a leading cause of cancer mortality in the UK, with approximately 48,000 new cases and 35,000 deaths annually. Early detection significantly improves outcomes, yet disparities in access and timely diagnosis persist, especially among socioeconomically disadvantaged and minority ethnic groups.

Project Period

December 2025 – August 2026. **Revised project Period:** January 2026 – September 2026

Project Objectives

Work collaboratively to create a robust AI lung cancer predictive tool tailored to South West London, but capable of scalability, with the aim of improving early lung cancer detection, both within the targeted lung health check population and those falling outside the inclusion criteria.

Patient Specific:

Reduction in time for patients to access appropriate treatments. Reduction in delay for patients for follow-up and review of their treatment thereby having a potential to reduce complications associated with their treatment. Improvement in patient experience by ensuring a quicker more streamlined process to treatment decisions.

NHS Specific:

Increase the number of appropriate referrals through the National Optimal Lung Cancer Pathway (NOLCP) from Primary Care. Facilitating faster access to specialist services for appropriate patients. Reduction in health inequalities.

Johnson and Johnson company specific:

A successful project will be example of a successful collaboration with the NHS.

The project can be used as a case study to be utilised with other NHS organisations, to develop and scale solutions to similar/different NHS challenges.

Resource Allocation

Johnson & Johnson will provide £78,000 to fund the creation of an AI Lung Cancer predictive tool, tailored to South West London, but capable of scalability with the aim of improving early lung cancer detection

In addition, 80 hours of Johnson & Johnson colleagues' time will be provided to support the project through all stages of delivery from planning to evaluation.

University Hospitals Leicester will provide £31,246 to support the creation of the AI Lung Cancer predictive tool and an additional 456 hours of time to the project.

Contact Details

Johnson and Johnson company: Maria Walsh, Business Unit Director.

NHS South West London ICB, Martin Ellis, Chief Digital Information Officer.